CompletedNCT01190267

Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)

Researchers studied asenapine, tracking side effects to assess long-term safety and tolerability in young people with schizophrenia.

Medication studyAges 12–17

The study in practice

Understand this study

Researchers studied asenapine, tracking side effects to assess long-term safety and tolerability in young people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 12 years to 17 years. Other eligibility criteria applied.

Study clarity

Study start dateStarted: September 28, 2010

Recruitment status: Completed
Enrollment listed in the registry: 204
Sponsor: Organon and Co
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Not clearly listed
Age range: From 12 Years to 17 Years
Official registry ID: NCT01190267
Official title: Show the full official title
A 26-week, Multi-center, Open-label, Flexible Dose, Long-term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia

Completed

Locations not listed

FAQ

What did researchers investigate?

Researchers studied asenapine, tracking side effects to assess long-term safety and tolerability in young people with schizophrenia.

Who is behind this study?

The study sponsor is Organon and Co.

Did this study involve medication?

Yes. The study involved medication, including asenapine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 12 years to 17 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.